z-logo
Premium
Transcript and Kinase Analysis of Epithelial to Mesenchymal Transition reversion by occludin in a Raf expressing epithelial cell line
Author(s) -
Hilgarth Roland S,
Mrsny Randall
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.242.9
Subject(s) - reversion , occludin , epithelial–mesenchymal transition , microbiology and biotechnology , line (geometry) , kinase , cell culture , chemistry , biology , transition (genetics) , tight junction , gene , genetics , biochemistry , phenotype , mathematics , geometry
Epithelial Tight junction proteins have been reported to play an important role in regulating epithelial cell polarity. Epithelial to mesenchymal transition is associated with loss of epithelial polarity and is observed during carcinogenesis and embryonic development. In previous studies we have demonstrated that the tight junction protein, occludin, suppresses Raf induced EMT in Pa4 model epithelial cells. To analyze the extent to which occludin rescues the EMT phenotype, we compared the transcriptome of the parent cell line, Pa4 to Pa4 cells expressing Raf (Pa4‐Raf1) and the EMT corrected cell line, Pa4‐Raf‐occludin. Remarkably, occludin expression in Pa4‐Raf1 cells resulted in a 98% correction of the transcriptome to that of the parental epithelial cell line suggesting an almost complete reversion of EMT in the Pa4‐Raf‐occludin cell line. Additionally, we performed a global kinase array (kinome) of these cell lines. Analogous to the genotypic reversion, the kinome analysis revealed that the majority of kinase/phosphatase activities reverted back to the original levels observed in the parental cell line. In conclusion, these analyses identify a critical role of occludin in regulating Raf induced EMT at the transcriptome and kinome level.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here